Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Neuroblastoma 9Melanoma 4Ganglioneuroblastoma 4Triple Negative Breast Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Transplant-Related Hematologic Malignancy 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

Dexamethasone 238Lenalidomide 145daratumumab 123Bortezomib 101pomalidomide 86Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40fludarabine 36belantamab mafodotin 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × sargramostim × 1 year × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡